Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE CYSTO versus RENOVIST II.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE CYSTO versus RENOVIST II.
HYPAQUE-CYSTO vs RENOVIST II
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HYPAQUE-CYSTO (diatrizoate meglumine) is a radiopaque contrast agent that absorbs x-rays, providing contrast in radiographic imaging. It acts as an iodinated contrast medium.
RENOVIST II is a radiographic contrast agent that contains diatrizoate meglumine and diatrizoate sodium. It increases the radiopacity of vascular structures and organs by attenuating X-rays due to the high atomic number of iodine atoms in the molecule.
Intravesical instillation: 100-300 mL of 30% solution for retrograde cystourethrography; single administration.
1-2 mL/kg IV bolus, not to exceed 150 mL total; may be repeated once if necessary.
None Documented
None Documented
Terminal elimination half-life: 1.5–2.5 hours (normal renal function). Prolonged in renal impairment.
1.2 hours in patients with normal renal function; prolonged to 8–12 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion via glomerular filtration: >95% unchanged within 24 hours. Fecal excretion: <5%.
Renal: 95% as unchanged drug via glomerular filtration; fecal: <5%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent